RecruitingNot ApplicableNCT05401162

Chemotherapy Supported by Autologous Hematopoietic Stem Cells

Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion

Sponsor

Chongqing University Cancer Hospital

Enrollment

40 participants

Start Date

Apr 15, 2022

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer

Summary

The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether collecting and re-infusing a patient's own stem cells during high-dose chemotherapy can help protect the bone marrow and reduce side effects in women with recurrent ovarian cancer. **You may be eligible if...** - You are a woman aged 18 to 60 - You have been diagnosed with recurrent or metastatic ovarian cancer confirmed by pathology - You require chemotherapy - Your overall health is good (ECOG ≤1) and you are expected to survive at least 3 months - You are pre-menopausal or have been post-menopausal for at least 1 year **You may NOT be eligible if...** - You have significant heart, liver, kidney, or bone marrow problems - You are currently pregnant or breastfeeding - You have an active serious infection - You have received prior bone marrow transplant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAutologous blood transfusion with haematopoietic stem cells

Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.

Locations(1)

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05401162

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

NCT067605071 location

Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

NCT071674331 location

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467164 locations